Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
Both ganglioside GD2-specific immunotherapy and antibody-drug conjugates (ADCs), as a class of targeted drugs, have demonstrated clinical success as solid tumor therapies in recent years, yet practically no research has been carried out on ADCs directed to ganglioside GD2. In a new study, scientists from the Department of immunology at IBCh RAS in collaboration with colleagues from other Russian institutes for the first time show that clinically relevant anti-GD2 antibody-drug conjugates manifest potent and highly selective cytotoxicity in a wide panel of cell lines with varying GD2 expression and strongly inhibit tumor growth in mouse models of GD2-positive solid cancer. The work is published in the Journal for ImmunoTherapy of Cancer. Learn more
19 июля 2022 года